Arrowhead Reports Positive Phase 1/2a Data For Alzheimer's Candidate ARO-MAPT

Arrowhead's Alzheimer's drug reduced tau in a Phase I/IIa trial. J&J's posdinemab failed in Phase IIb. Eisai's etalanetug, Biogen's diranersen, TauRx's hydromethylthionine, and Annovis Bio's buntanetap are in development. The Alzheimer's market is projected to grow from $2.4bn to $14.7bn by 2033, with a CAGR of 20%.

Arrowhead Pharmaceuticals (ARWR) shares rose over 4% premarket Wednesday after reporting positive early-stage trial data for its Alzheimer's drug, ARO-MAPT, using its TRiM delivery platform.

Arrowhead Pharmaceuticals (ARWR) shares rose 6.7% after reporting positive clinical data for its Alzheimer's drug ARO-MAPT, which reduced tau proteins by 73% in healthy volunteers. The drug showed sustained effects and mild side effects, with further trials planned. The company aims to treat Alzheimer's and other tauopathies.

Arrowhead Pharmaceuticals (ARWR) stock rose 8.4% in pre-market trading after announcing interim Phase 1/2a results for ARO-MAPT, showing a 73% mean reduction in cerebrospinal fluid total tau. The company's TRiM™ platform was clinically validated, and the safety profile was reassuring. The FDA previously granted plozasiran entry into the STAR program. The stock traded at $63, up from a prior close of $58.13.

Arrowhead Pharmaceuticals (ARWR) reported interim Phase 1/2a study results for ARO-MAPT, an Alzheimer’s drug. The study showed a 73% mean reduction in cerebrospinal fluid total tau at Day 105, with a maximum individual reduction of 85%. The treatment was generally well tolerated. The company plans to continue enrollment in early Alzheimer’s disease cohorts, with data updates expected in 2027.

Arrowhead Pharmaceuticals reported interim Phase 1/2a data showing its drug ARO-MAPT reduced CSF total tau by up to 85% in healthy volunteers, with a mean reduction of 73% at Day 105. The drug was generally well tolerated. This is early-stage data for Arrowhead's CNS RNAi platform.